<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        118-186-00
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2000
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        JULMENTIN 156.25 MG POWDER FOR SUSP
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        AMOXICILLIN,CLAVULANIC ACID
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        125,31.25
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg/ml
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Powder for oral suspension
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        100
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Bottle
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 25°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        14.55
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Gulf Pharmaceutical Industries (Julphar)" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Gulf Pharmaceutical Industries (Julphar)
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 359]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Cigalah Group
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Gulf Pharmaceutical Industries (Julphar)
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        J01CR02
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Julmentin</strong> is an antibiotic and works by killing bacteria that cause infections. It contains two different medicines called amoxicillin and clavulanic acid. Amoxicillin belongs to a group of medicines called &ldquo;penicillins&rdquo; that can sometimes be stopped from working (made inactive). The other active component (clavulanic acid) stops this from happening.</p><p><strong>Julmentin</strong> is used in babies and children to treat the following infections:</p><p>&bull;&nbsp; Middle ear and sinus infections</p><p>&bull;&nbsp; Respiratory tract infections</p><p>&bull;&nbsp; Urinary tract infections</p><p>&bull;&nbsp; Skin and soft tissue infections including dental infections</p><p>&bull;&nbsp; Bone and joint infections.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not give your child Julmentin: </strong></p><p>&bull;&nbsp; If they are allergic to amoxicillin, clavulanic acid, penicillin or any of the other ingredients of this medicine (listed in section 6)</p><p>&bull;&nbsp; If they have ever had a severe allergic reaction to any other antibiotic. This can include a skin rash or swelling of the face or throat.</p><p>&bull;&nbsp; If they have ever had liver problems or jaundice (yellowing of the skin) when taking an antibiotic.</p><p><strong>Do not give Julmentin to your child if any of the above applies to your child</strong>. If you are not sure, talk to their doctor or pharmacist before giving <strong>Julmentin</strong>.</p><p><strong>Warning and Precautions</strong></p><p>Check with their doctor, pharmacist or nurse before giving your child <strong>Julmentin</strong> if they:</p><p>&bull;&nbsp; Have glandular fever</p><p>&bull;&nbsp; Are being treated for liver or kidney problems</p><p>&bull;&nbsp; Are not passing water regularly.</p><p>If you are not sure if any of the above applies to your child, talk to their doctor or pharmacist before giving <strong>Julmentin</strong>. <strong>&nbsp;</strong></p><p>In some cases, your doctor may investigate the type of bacteria that is causing your child&rsquo;s infection. Depending on the results, your child may be given a different strength of <strong>Julmentin</strong> or a different medicine.</p><p><strong>Conditions you need to look out for</strong></p><p><strong>Julmentin</strong> can make some existing conditions worse, or cause serious side effects. These include allergic reactions, convulsions (fits) and inflammation of the large intestine. You must look out for certain symptoms while your child is taking <strong>Julmentin</strong>, to reduce the risk of any problems. See &lsquo;Conditions you need to look out for&rsquo; in <strong>section 4. </strong></p><p><strong>Blood or urine tests</strong></p><p>If your child is having blood tests (such as red blood cell status tests or liver function tests) or urine tests (for glucose), let the doctor or nurse know that they are taking <strong>Julmentin</strong>. This is because <strong>Julmentin</strong> can affect the results of these types of tests.</p><p><strong>Other medicines and Julmentin </strong></p><p>Tell your doctor or pharmacist if your child is taking, has recently taken or might take any other medicines.</p><p>&bull;&nbsp; If your child is taking allopurinol (used for gout) with <strong>Julmentin</strong>, it may be more likely that they will have an allergic skin reaction.</p><p>&bull;&nbsp; If your child is taking probenecid (used for gout), your doctor may decide to adjust the dose of <strong>Julmentin</strong>.</p><p>&bull;&nbsp; If medicines to help stop blood clots (such as warfarin) are taken with <strong>Julmentin</strong> then extra blood tests may be needed.</p><p><strong>Julmentin</strong> can affect how methotrexate (a medicine used to treat cancer or rheumatic diseases) works.</p><p><strong>Julmentin</strong> may affect how mycophenolate mofetil (a medicine used to prevent the rejection of transplanted organs) works.</p><p><strong>Pregnancy, breast-feeding and fertility </strong></p><p>This subsection is not applicable for the <strong>Julmentin</strong> Suspension since they are intended for use in children; however the following information is relevant to the active ingredients, amoxicillin and clavulanic acid.</p><p>If the patient who is about to take this medicine is pregnant or breast-feeding, thinks they may be pregnant or are planning to have a baby, ask the doctor or pharmacist for advice before taking this medicine.</p><p><strong>Driving and using machines </strong></p><p>This subsection is not applicable for the <strong>Julmentin</strong> Suspension since they are intended for use in children; however the following information is relevant to the active ingredients, amoxicillin and clavulanic acid.</p><p><strong>Julmentin</strong> can have side effects and the symptoms may make you unfit to drive.</p><p>Do not drive or operate machinery unless you are feeling well.</p><p><strong>Important information of some ingredients of Julmentin</strong></p><p><strong>Julmentin </strong>contains saccharin. If you have been told by your doctor that your child have intolerance to some sugars, talk to your doctor before giving this medicine to your child</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always give this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure.</p><p><strong>How to give Julmentin</strong></p><p>&bull;&nbsp; Always shake the bottle well before each dose</p><p>&bull;&nbsp; Give with a meal</p><p>&bull;&nbsp; Space the doses evenly during the day, at least 4 hours apart. Do not take 2 doses in 1 hour.</p><p>&bull;&nbsp; Do not give your child <strong>Julmentin</strong> for more than 2 weeks. If your child still feels unwell they should go back to &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;see the doctor.</p><p><strong><u>Directions for Reconstitution: </u></strong></p><p>&bull;&nbsp; <strong>Julmentin Suspension 156mg: </strong></p><p>Loosen powder, add approximately 60mL of water or add water to ⅔ of the mark on the bottle and shake vigorously in an inverted position, allow it to stand for 5 minutes and then add water up to the mark and shake vigorously&nbsp;until a homogeneous suspension is achieved.&nbsp;Shake well before taking each dose.</p><p>&bull;&nbsp; <strong>Julmentin Forte Suspension 312mg:</strong></p><p>Loosen powder, add 85mL of water in two portions and shake well after each addition, or add water to ⅔ of the mark on the bottle. Shake well and make up to the mark. Shake well.</p><p><strong><u>Dosage:</u></strong></p><p><strong>Adults and children weighing 40 kg or over </strong></p><p>&bull;&nbsp; This suspension is not usually recommended for adults and children weighing 40 kg and over. Ask your doctor or pharmacist for advice.</p><p><strong>Children weighing less than 40 kg </strong></p><p>All doses are worked out depending on the child&rsquo;s bodyweight in kilograms.</p><p>&bull;&nbsp; Your doctor will advise you how much <strong>Julmentin </strong>you should give to your baby or child.</p><p>&bull;&nbsp; You will be provide with a measuring device. You should use this to give the correct dose to your baby or child.</p><p>&bull;&nbsp; <strong>Julmentin Suspension 156mg: </strong></p><p>- Recommended dose &ndash; 20 mg/5 mg/kg/day (0.8 mL of suspension/kg/day) to 60 mg/15mg/kg/day (2.4 mL of suspension/kg/day) given in three divided doses.</p><p>&bull;&nbsp; <strong>Julmentin Forte Suspension 312mg: </strong></p><p>- Recommended dose &ndash; 20 mg/5mg/kg/day (0.4 mL of suspension/kg/day) to 60 mg/15 mg/kg/day (1.2 mL of suspension/kg/day) given in three divided doses.</p><p><strong>&nbsp;Patients with kidney and liver problems </strong></p><p>&bull;&nbsp; If your child has kidney problems the dose might be lowered. A different strength or a different medicine may be chosen by your doctor.</p><p>&bull;&nbsp; If your child has liver problems they may have more frequent blood tests to see how their liver is working.</p><p><strong>If you give more Julmentin than you should</strong></p><p>If you give your child too much <strong>Julmentin</strong>, signs might include an upset stomach (feeling sick, being sick or diarrhoea) or convulsions. Talk to their doctor as soon as possible. Take the medicine bottle to show the doctor.</p><p><strong>If you forget to give Julmentin</strong></p><p>If you forget to give your child a dose, give it as soon as you remember. You should not give your child the next dose too soon, but wait about 4 hours before giving the next dose. Do not take a double dose to make up for a forgotten dose.</p><p><strong>If your child stops taking Julmentin</strong></p><p>Keep giving your child <strong>Julmentin</strong> until the treatment is finished, even if they feel better. Your child needs every dose to help fight the infection. If some bacteria survive they can cause the infection to come back.</p><p><strong>If you have any further questions on the use of this product, ask your doctor, pharmacist or nurse</strong><strong>.</strong></p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them. The side effects below may happen with this medicine.</p><p><strong>Conditions you need to look out for </strong></p><p><strong>Allergic reactions: </strong></p><p>&bull;&nbsp; Skin rash</p><p>&bull;&nbsp; Inflammation of blood vessels (vasculitis) which may be visible as red or purple raised spots on the skin, but can affect other parts of the body</p><p>&bull;&nbsp; Fever, joint pain, swollen glands in the neck, armpit or groin</p><p>&bull;&nbsp; Swelling, sometimes of the face or throat (angioedema), causing difficulty in breathing</p><p>- Collapse</p><p><strong>Contact a doctor immediately </strong>if your child gets any of these symptoms<strong>. Stop taking Julmentin. </strong></p><p><strong>Inflammation of large intestine </strong></p><p>Inflammation of the large intestine, causing watery diarrhoea usually with blood and mucus, stomach pain and/or fever.</p><p><strong>Contact your doctor as soon as possible for advice if your child gets these symptoms. </strong></p><p><strong>Very common side effects </strong></p><p>These may affect more than 1 in 10 people</p><p>&bull;&nbsp; Diarrhoea (in adults).</p><p><strong>Common side effects </strong></p><p>These may affect up to 1 in 10 people</p><p>&bull;&nbsp; Thrush (candida - a yeast infection of the vagina, mouth or skin folds)</p><p>&bull;&nbsp; Feeling sick (nausea), especially when taking high doses</p><p>&sect; If affected take <strong>Julmentin</strong> with a meal</p><p>&bull;&nbsp; Vomiting</p><p>&bull;&nbsp; Diarrhoea (in children).</p><p><strong>Uncommon side effects </strong></p><p>These may affect up to 1 in 100 people</p><p>&bull;&nbsp; Skin rash, itching</p><p>&bull;&nbsp; Raised itchy rash (<em>hives</em>)</p><p>&bull;&nbsp; Indigestion</p><p>&bull;&nbsp; Dizziness</p><p>&bull;&nbsp; Headache.</p><p><u>Uncommon side effects that may show up in blood tests: </u></p><p>&bull;&nbsp; Increase in some substances (<em>enzymes</em>) produced by the liver</p><p><strong>Rare side effects </strong></p><p>These may affect up to 1 in 1000 people</p><p>&bull;&nbsp; Skin rash, which may blister, and looks like small targets (central dark spots surrounded by a paler area, with a dark ring around the edge - <em>erythema multiforme</em>)</p><p>&sect; If you notice any of these symptoms contact a doctor urgently.</p><p><u>Rare side effects that may show up in blood tests: </u></p><p>&bull;&nbsp; Low number of cells involved in blood clotting.</p><p>&bull;&nbsp; Low number of white blood cells.</p><p><strong>Frequency not known</strong></p><p>Frequency cannot be estimated from available data.</p><p>&bull;&nbsp; Allergic reactions (see above)</p><p>&bull;&nbsp; Inflammation of the large intestine (see above)</p><p>&bull;&nbsp; Inflammation of the protective membrane surrounding the brain (aseptic meningitis)</p><p>&bull;&nbsp; Serious skin reactions:</p><p>&sect; a widespread rash with blisters and peeling skin, particularly around the mouth, nose, eyes and genitals (<em>Stevens-Johnson syndrome</em>), and a more severe form, causing extensive peeling of the skin (more than 30% &nbsp;of the body surface - <em>toxic epidermal necrolysis</em>)</p><p>&sect; widespread red skin rash with small pus-containing blisters (<em>bullous exfoliative dermatitis</em>)</p><p>&sect; a red, scaly rash with bumps under the skin and blisters (<em>exanthemous pustulosis</em>).</p><p>&sect; flu-like symptoms with a rash, fever, swollen glands, and abnormal blood test results (including increased white blood cells (eosinophilia) and liver enzymes) (Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS)).</p><p><strong>Contact a doctor immediately if your child gets any of these symptoms.</strong></p><p>&bull;&nbsp; Inflammation of the liver (hepatitis)</p><p>&bull;&nbsp; Jaundice, caused by increases in the blood of bilirubin (a substance produced in the liver) which may make your child&rsquo;s skin and whites of the eyes appear yellow</p><p>&bull;&nbsp; Inflammation of tubes in the kidney</p><p>&bull;&nbsp; Blood takes longer to clot</p><p>&bull;&nbsp; Hyperactivity</p><p>&bull;&nbsp; Convulsions (in people taking high doses of <strong>Julmentin</strong> or who have kidney problems)</p><p>&bull;&nbsp; Black tongue which looks hairy</p><p>&bull;&nbsp; Stained teeth (in children), usually removed by brushing.</p><p><u>Side effects that may show up in blood or urine tests: </u></p><p>&bull;&nbsp; Severe reduction in the number of white blood cells</p><p>&bull;&nbsp; Low number of red blood cells (<em>haemolytic anaemia</em>)</p><p>&bull;&nbsp; Crystals in urine.</p><p><strong><u>To report any side effect(s): </u></strong></p><p>If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via:</p><p>&sect; <strong>Saudi</strong><strong> Arabia:</strong></p><p><strong>&nbsp; &nbsp;&nbsp; The National Pharmacovigilance Centre (NPC):</strong></p><p>-&nbsp;&nbsp; <strong>SFDA Call Centre:</strong> 19999</p><p>-&nbsp;&nbsp; <strong>E-mail:</strong> npc.drug@sfda.gov.sa</p><p>-&nbsp;&nbsp; <strong>Website: </strong>https://ade.sfda.gov.sa/</p><p>&sect; <strong>Other</strong><strong> GCC States:</strong></p><p>Please contact the relevant competent authority</p><p>By reporting side effects, you can help provide more information on the safety of this medicine.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&bull; Keep out of the reach and sight of children.</p><p>&bull; Do not give <strong>Julmentin</strong> after the expiry date which is stated on the carton and the inner label.</p><p>&bull; Before reconstitution, store below 30&deg;C, in a dry place, protected from light.</p><p>&bull; After reconstitution, store in a refrigerator (2-8&deg;C) and use within 7 days. Shake well before use.</p><p>&bull; Do not give <strong>Julmentin</strong> if you notice any visible sign of deterioration.</p><p>&bull; Medicines should<em> </em>not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help to protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong><u>Julmentin</u></strong><strong><u> Suspension 156mg:</u></strong></p><p>Each teaspoonful (5mL) of the reconstituted suspension contains:</p><p>Active ingredients<em>:</em> Amoxicillin trihydrate equivalent to 125mg amoxicillin and potassium clavulanate equivalent to 31.25mg clavulanic acid.</p><p>The other ingredients: Citric acid anhydrous, sodium citrate, sodium benzoate, microcrystalline cellulose, xanthan &nbsp;gum, colloidal silicon dioxide, saccharin sodium, strawberry flavour, and mannitol.</p><p><strong><u>Julmentin</u></strong><strong><u> Forte Suspension 312mg:</u></strong></p><p>Each teaspoonful (5mL) of the reconstituted suspension contains:</p><p>Active ingredients<em>:&nbsp; </em>Amoxicillin trihydrate equivalent to 250mg amoxicillin and potassium clavulanate equivalent to 62.5mg clavulanic acid.</p><p>The other ingredients: Citric acid anhydrous, sodium citrate, sodium benzoate, microcrystalline cellulose, xanthan gum, colloidal silicon dioxide, saccharin sodium, cherry flavour and mannitol.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                
Julmentin and Julmentin Forte powder for oral suspension are available in packs containing one bottle (100mL after reconstitution) each along with measuring spoon.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Gulf Pharmaceutical Industries &quot; Julphar&quot;.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                28/03/2022
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL"><strong>جلمنتين </strong>مضاد حيوي يعمل عن طريق القضاء على البكتيريا المسببة للعدوى. ويحتوي على نوعين مختلفين من المواد الدوائية وهما أموكسيسيلين وحمض كلافيولانيك. ينتمي أموكسيسيلين إلى مجموعة من الأدوية التي تعرف باسم &quot;البنسيلينات&quot; والذي من الممكن في بعض الأحيان أن تتوقف آلية عمله (يصبح غير نشط). بينما تعمل المادة الأخرى في هذا الدواء (حمض كلافيولانيك) على منع حدوث ذلك الأمر.</p><p dir="RTL">يستخدم <strong>جلمنتين </strong>من قبل الرضع والأطفال لعلاج حالات العدوى التالية:</p><p dir="RTL">&bull;&nbsp; عدوى الأذن الوسطى والجيوب الأنفية</p><p dir="RTL">&bull;&nbsp; عدوى الجهاز التنفسي</p><p dir="RTL">&bull;&nbsp; عدوى المسالك البولية</p><p dir="RTL">&bull;&nbsp; عدوى الجلد والأنسجة الرخوة بما في ذلك عدوى الأسنان</p><p dir="RTL">&bull;&nbsp; عدوى العظام والمفاصل</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>يجب عليك عدم إعطاء جلمنتين لطفلك في الحالات التالية:</strong></p><p dir="RTL">&bull;&nbsp; إذا كان يعاني من الحساسية تجاه أموكسيسيلين، حمض الكلافيولانيك، البنسيلين أو أياً من المكونات الأخرى في هذا الدواء (المذكورة في قسم 6)</p><p dir="RTL">&bull;&nbsp; إذا عانى مسبقاً من تفاعل تحسسي شديد تجاه أياً من المضادات الحيوية الأخرى. من الممكن أن يتضمن ذلك على حدوث طفح جلدي أو تورم في الوجه أو الحلق</p><p dir="RTL">&bull;&nbsp; إذا عانى مسبقاً من مشاكل في الكبد أو يرقان (اصفرار الجلد) عند تناول المضادات الحيوية.</p><p dir="RTL"><strong>&nbsp;</strong><strong>يجب عدم إعطاء جلمنتين لطفلك إذا كان أياً من المذكور أعلاه ينطبق عليه. </strong>يرجى منك إخبار الطبيب المعالج أو الصيدلي الذي تتعامل معه قبل إعطاء<strong> جلمنتين </strong>مالم تكن متأكداً من ذلك.</p><p dir="RTL"><strong>&nbsp;تحذيرات واحتياطات </strong></p><p dir="RTL">&nbsp;يرجى منك استشارة الطبيب المعالج، أو الصيدلي الذي تتعامل معه أو الممرض قبل إعطاء <strong>جلمنتين </strong>لطفلك إذا كان :</p><p dir="RTL">&bull;&nbsp; &nbsp;يعاني من الحمى الناجمة عن اضطرابات في الغدد</p><p dir="RTL">&bull;&nbsp; &nbsp;يتلقى علاجاً لمشاكل في الكبد أو الكلى</p><p dir="RTL">&bull;&nbsp; &nbsp;يعاني من عدم التبول بصورة منتظمة</p><p dir="RTL">يرجى منك التحدث إلى الطبيب المعالج أو الصيدلي الذي تتعامل معه قبل إعطاء<strong> جلمنتين،</strong> مالم تكن متأكداً ما إذا كان أياً من المذكور أعلاه ينطبق على طفلك.</p><p dir="RTL">في بعض الحالات، قد يقوم الطبيب المعالج بإجراء فحص مختبري لمعرفة نوع البكتيريا المسببة للعدوى لدى الطفل. وبناءً على هذه النتائج، قد يتم إعطاء <strong>جلمنتين </strong>لطفلك بتركيز مختلف أو إعطائه أدوية أخرى.</p><p dir="RTL"><strong>الحالات التي تتطلب منك الانتباه</strong></p><p dir="RTL">من الممكن أن يؤدي <strong>جلمنتين </strong>إلى<strong> </strong>تدهور بعض الحالات المرضية التي يعاني منها طفلك في الوقت الحالي، أو يؤدي إلى حدوث تأثيرات جانبية خطيرة. بما في ذلك تفاعلات تحسسية، اختلاجات (نوبات تشنجية) والتهاب الأمعاء الغليظة. يجب عليك الانتباه من ظهور أعراض معينة أثناء تناول طفلك <strong>جلمنتين</strong>، وذلك للتقليل من خطر حدوث أية مشاكل. انظر، &quot;الحالات التي تتطلب منك الانتباه&quot; المذكورة <strong>في قسم 4</strong>.</p><p dir="RTL"><strong>فحوصات الدم أو البول</strong></p><p dir="RTL">إذا كان طفلك سوف يخضع لفحوصات الدم (على سبيل المثال فحوصات خلايا الدم الحمراء أو فحوصات وظائف الكبد) أو فحوصات البول (للكشف عن الجلوكوز)، &nbsp;فيرجى منك إخبار الطبيب المعالج أو الممرض بأن طفلك يتناول<strong> جلمنتين</strong>. وذلك لأن من الممكن أن يؤثر <strong>جلمنتين </strong>على نتائج هذه الفحوصات.</p><p dir="RTL"><strong>تناول </strong><strong>جلمنتين بالتزامن </strong><strong>مع الأدوية الأخرى:</strong></p><p dir="RTL">يرجى منك إخبار طبيبك المعالج أو الصيدلي الذي تتعامل معه إذا كان طفلك يتناول، تناول مؤخراً أو قد يتناول أية أدوية أخرى.</p><p dir="RTL">&bull;&nbsp; إذا كان طفلك يتناول ألوبيورينول (دواء يستخدم لعلاج النقرس) بالتزامن مع <strong>جلمنتين</strong>، &nbsp;قد يكون أكثر عرضة لحدوث تفاعل تحسسي جلدي.</p><p dir="RTL">&bull;&nbsp; إذا كان طفلك يتناول بروبنسيد (دواء يستخدم لعلاج النقرس)، فقد يقرر طبيبك المعالج تعديل مقدار الجرعة من <strong>جلمنتين</strong>.</p><p dir="RTL">&bull;&nbsp; إذا كان طفلك يتناول الأدوية التي تعمل على منع تخثر الدم (على سبيل المثال وارفارين) بالتزامن مع <strong>جلمنتين</strong>، فسوف يتطلب ذلك إجراء فحوصات دم إضافية.</p><p dir="RTL">من الممكن أن يؤثر<strong> جلمنتين </strong>على آلية عمل ميثوتركسات (دواء يستخدم لعلاج السرطان أو الأمراض الروماتيزمية).</p><p dir="RTL">من الممكن أن يؤثر<strong> جلمنتين </strong>على آلية عمل مايكوفينولات موفيتل (دواء يستخدم لمنع رفض الجسم للأعضاء المزروعة).</p><p dir="RTL"><strong>الحمل</strong><strong>، </strong><strong>الرضاعة الطبيعية والخصوبة</strong></p><p dir="RTL">هذه الجزئية غير قابلة للتطبيق بالنسبة لمعلق <strong>جلمنتين</strong>، حيث أنه معد للاستعمال من قبل الأطفال، ومع ذلك فإن المعلومات التالية تتعلق بالمواد الفعالة، أموكسيسيلين وحمض كلافيولانيك.</p><p dir="RTL">إذا كانت المريضة التي ستتناول هذا الدواء حاملاً أو مرضعة، تعتقد أنها حامل أو كانت تنوي الإنجاب، فإنه ينصح باستشارة الطبيب المعالج أو الصيدلي الذي تتعامل معه &nbsp;للحصول على المشورة الطبية قبل تناول هذا الدواء.</p><p dir="RTL"><strong>القيادة واستخدام الآلات</strong></p><p dir="RTL">هذه الجزئية غير قابلة للتطبيق بالنسبة لمعلق <strong>جلمنتين</strong>، حيث أنه معد للاستعمال من قبل الأطفال، ومع ذلك فإن المعلومات التالية تتعلق بالمواد الفعالة، أموكسيسيلين وحمض كلافيولانيك.</p><p dir="RTL">قد يسبب <strong>جلمنتين </strong>تأثيرات جانبية وأعراض التي يمكن أن تعيق قدرتك على القيادة. يجب عدم القيادة أو تشغيل الآلات ما لم تكن بصحة جيدة.</p><p dir="RTL"><strong>معلومات هامة حول بعض مكونات </strong><strong>جلمنتين</strong></p><p dir="RTL">يحتوي <strong>جلمنتين </strong>على السكارين. يرجى منك استشارة الطبيب المعالج قبل إعطاء هذا الدواء إذا كان قد أخبرك مسبقاً بأن طفلك يعاني من مشكلة تتمثل في عدم القدرة على تحمل بعض أنواع السكر.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يرجى منك دائماً إعطاء هذا الدواء<strong> </strong>لطفلك<strong> </strong>بدقة كما أخبرك الطبيب المعالج أو الصيدلي الذي تتعامل معه. يرجى منك استشارة طبيبك المعالج &nbsp;أو الصيدلي الذي تتعامل معه مالم تكن متأكداً من كيفية إعطاء هذا الدواء لطفلك.</p><p dir="RTL"><strong>كيفية إعطاء جلمنتين</strong></p><p dir="RTL">&bull;&nbsp; رج الزجاجة دائماً قبل إعطاء كل جرعة</p><p dir="RTL">&bull;&nbsp; يتم إعطاء الدواء مع وجبة الطعام.</p><p dir="RTL">&bull;&nbsp; يجب ترك فترة زمنية فاصلة بين الجرعات على مدار اليوم، ما لا يقل عن 4 ساعات بين الجرعات. يجب عدم إعطاء جرعتين خلال ساعة واحدة.</p><p dir="RTL"><strong>&bull;&nbsp; </strong>يجب عليك عدم إعطاء <strong>جلمنتين</strong> لطفلك لمدة تزيد عن أسبوعين. يجب عليك مراجعة الطبيب المعالج إذا لم تتحسن الحالة الصحية لطفلك.<strong> </strong></p><p dir="RTL"><strong><u>إرشادات التحضير </u></strong></p><p dir="RTL"><strong>&bull;&nbsp; </strong><strong>معلق جلمنتين 156 ملغم</strong></p><p dir="RTL">حرك المسحوق، قم بإضافة 60 ملليلتر من الماء أو أضف بعض من الماء على جزئين حتى ثلثي العلامة على الزجاجة ثم قم برج الزجاجة جيداً رأساً على عقب. اترك المعلق لمدة 5 دقائق. أكمل إضافة الماء حتى العلامة وقم برج الزجاجة جيدا حتى يتم الحصول على معلق متجانس. رج المعلق جيدا قبل تناول كل جرعة.</p><p dir="RTL"><strong>&bull;&nbsp; </strong><strong>معلق جلمنتين فورت 312 ملغم</strong></p><p dir="RTL">حرك المسحوق، أضف 85 ملليلتر من الماء على جزئين ورج جيداً بعد كل إضافة، أو أضف بعض الماء حتى ثلثي المسافة للعلامة على الزجاجة ورج جيداً ثم أكمل إضافة الماء حتى العلامة ورج جيداً.</p><p dir="RTL"><strong><u>مقدار الجرعة:</u></strong></p><p dir="RTL"><strong>البالغون والأطفال الذين تبلغ أوزانهم 40&nbsp; كيلوغرام فما فوق</strong></p><p dir="RTL">&bull;&nbsp; لا يوصى عادةً بتناول هذا المعلق من قبل البالغين والأطفال الذين تبلغ أوزانهم 40 كيلوغرام فما فوق. يرجى منك استشارة طبيبك المعالج أو الصيدلي الذي تتعامل معه للحصول على المشورة الطبية.</p><p dir="RTL"><strong>الأطفال الذين تقل أوزانهم عن 40 كيلوغرام</strong></p><p dir="RTL">يتم وصف جميع الجرعات اعتماداً على وزن جسم الطفل بالكيلوغرامات.</p><p dir="RTL">&bull;&nbsp; سوف يقدم لك طبيبك المعالج النصيحة حول مقدار الجرعة الواجب عليك إعطائها للرضيع أو للطفل من <strong>جلمنتين</strong>.</p><p dir="RTL">&bull;&nbsp; سوف يكون الدواء مزوداً بأداة للقياس. يجب عليك استخدامها لإعطاء الطفل أو الرضيع المقدار الصحيح من الجرعة.</p><p dir="RTL"><strong>&bull;&nbsp; </strong><strong>معلق جلمنتين 156 ملغم </strong></p><p dir="RTL">-&nbsp; مقدار الجرعة الموصى بها 20ملغم/ 5ملغم لكل كليوغرام من وزن جسم الطفل في اليوم (0.8 ملليلتر من المعلق/كيلوغرام/اليوم) لتصل إلى 60ملغم/15ملغم لكل كليوغرام من وزن جسم الطفل في اليوم (2.4 ملليلتر من المعلق/كيلوغرام/اليوم)&nbsp; ويتم إعطاؤها على جرعات مقسمة إلى&nbsp; 3 جرعات منفصلة.</p><p dir="RTL"><strong>&bull;&nbsp; </strong><strong>معلق جلمنتين فورت 312 ملغم</strong></p><p dir="RTL">-&nbsp; مقدار الجرعة الموصى بها 20ملغم/ 5ملغم لكل كليوغرام من وزن جسم الطفل في اليوم، (0.4 ملليلتر من المعلق/كيلوغرام/اليوم) لتصل إلى 60ملغم/15ملغم لكل كليوغرام من وزن جسم الطفل في اليوم (1.2 ملليلتر من المعلق/كيلوغرام/اليوم) ويتم إعطاؤها على جرعات مقسمة إلى&nbsp; 3 جرعات منفصلة.</p><p dir="RTL"><strong>المرضى الذين يعانون من مشاكل في الكلى والكبد</strong></p><p dir="RTL">&bull;&nbsp; إذا كان الطفل يعاني من مشاكل في الكلى فقد يتم تقليل مقدار الجرعة المعطاة. قد يختار الطبيب المعالج تركيزاً مختلفاً من الجرعات أو دواءً مختلفاً.</p><p dir="RTL">&bull;&nbsp; إذا كان الطفل يعاني من مشاكل في الكبد، فقد يكون بحاجة إلى إجراء فحوصات الدم بشكل دوري لمعرفة مدى كفاءة عمل الكبد.</p><p dir="RTL"><strong>إذا تم إعطاء </strong><strong>جلمنتين </strong><strong>بجرعة أكبر مما يجب</strong></p><p dir="RTL">إذا تم إعطاء <strong>جلمنتين </strong>بجرعة أكبر مما يجب للطفل، قد يؤدي ذلك إلى ظهور علامات بما في ذلك اضطراب في المعدة (الشعور بالإعياء، التوعك أو إسهال) أو اختلاجات. يرجى منك إخبار الطبيب المعالج بهذا الأمر في أسرع وقت ممكن. خذ زجاجة الدواء معك لإظهارها للطبيب المعالج.</p><p dir="RTL"><strong>إذا سهوت عن إعطاء جلمنتين لطفلك</strong></p><p dir="RTL">إذا سهوت عن إعطاء الجرعة لطفلك، قم بإعطائه الجرعة في أقرب وقت حال تذكرها. ويجب عليك الانتظار 4 ساعات قبل إعطاء طفلك الجرعة التالية. يجب عليك عدم مضاعفة الجرعة للتعويض عن الجرعة التي سهوت عن إعطائها لطفلك.</p><p dir="RTL"><strong>إذا توقفت عن إعطاء جلمنتين لطفلك</strong></p><p dir="RTL">يرجى منك إعطاء <strong>جلمنتين </strong>لطفلك<strong> </strong>إلى أن تنتهي مدة العلاج المقررة حتى لو تحسنت حالة الطفل الصحية. حيث يحتاج طفلك إلى كل جرعة من &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;الدواء الموصوف له للمساعدة على القضاء على العدوى. في حال لم يتم القضاء على جميع البكتيريا المسببة للعدوى فقد يتسبب ذلك في معاودة حدوث العدوى مرة أخرى.</p><p dir="RTL"><strong>يرجى منك استشارة الطبيب المعالج، الصيدلي الذي تتعامل معه أو الممرض، إذا كان لديك أية أسئلة إضافية حول استخدام هذا الدواء.</strong></p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">شأنه شأن جميع الأدوية، من الممكن أن يؤدي هذا الدواء<strong> </strong>إلى حدوث تأثيرات جانبية، ولكنها قد لا تحدث لكل شخص. &nbsp;قد تحدث التأثيرات الجانبية المذكورة أثناء فترة تناول هذا الدواء</p><p dir="RTL"><strong>الحالات التي تتطلب منك الإنتباه</strong></p><p dir="RTL"><strong>تفاعلات تحسسية</strong>:</p><p dir="RTL">&bull;&nbsp; طفح جلدي.</p><p dir="RTL">&bull;&nbsp; التهاب الأوعية الدموية&nbsp; الذي يظهر على شكل بقع حمراء أو بنفسجية مرتفعة عن سطح الجلد، ولكن من الممكن أن يؤثر على أجزاء أخرى من الجسم.</p><p dir="RTL">&bull;&nbsp; حمى، ألم في المفاصل، تورم الغدد في منطقة الرقبة، الفخذين أو الإبطين.</p><p dir="RTL">&bull;&nbsp; تورم، والذي يشمل في بعض الأحيان الوجه أو الحلق (وذمة وعائية)، مسببة بذلك صعوبة في التنفس.</p><p dir="RTL">&bull;&nbsp; تدهورعام في الصحة.</p><p dir="RTL"><strong>يرجى منك التواصل مع الطبيب المعالج&nbsp; على </strong>الفور إذا تعرض الطفل لأياً من تلك الأعراض. كما يجب عليك <strong>التوقف عن إعطاء جلمنتين</strong>.</p><p dir="RTL"><strong>التهاب الأمعاء الغليظة</strong></p><p dir="RTL">قد يؤدي التهاب الأمعاء الغليظة<strong> </strong>إلى حدوث إسهال مائي مصحوب عادةً بخروج دم و مخاط، ألم في المعدة و/أو حمى.</p><p dir="RTL"><strong>يرجى منك التواصل مع الطبيب المعالج في أقرب وقت ممكن لطلب المشورة الطبية في حال تعرض الطفل لأياً من هذه الأعراض</strong>.<strong> &nbsp;</strong></p><p dir="RTL"><strong>التأثيرات الجانبية الشائعة جداً</strong></p><p dir="RTL">قد تؤثر على أكثر من شخص واحد من كل 10 أشخاص.</p><p dir="RTL">&bull;&nbsp; إسهال (لدى البالغين).</p><p dir="RTL"><strong>التأثيرات الجانبية الشائعة</strong></p><p dir="RTL">قد تؤثر على ما يصل إلى شخص واحد من كل 10 أشخاص</p><p dir="RTL">&bull;&nbsp; داء القلاع (الكانديدا &ndash; عدوى الخميرة في المهبل، الفم أوثنايا الجلد).</p><p dir="RTL">&bull;&nbsp; الشعور بالإعياء (غثيان)، وبصفة خاصة عند تناول الجرعات العالية.</p><p dir="RTL">&sect;&nbsp; في حال الإصابة بذلك، ينصح بتناول <strong>جلمنتين </strong>مع وجبات الطعام.</p><p dir="RTL">&bull;&nbsp; تقيؤ.</p><p dir="RTL">&bull;&nbsp; إسهال (لدى الأطفال).</p><p dir="RTL"><strong>التأثيرات الجانبية الغير شائعة</strong></p><p dir="RTL">&nbsp;قد تؤثر على ما يصل إلى شخص واحد من كل 100 شخص</p><p dir="RTL">&bull;&nbsp; طفح جلدي، حكة.</p><p dir="RTL">&bull;&nbsp; طفح جلدي مرتفع عن سطح الجلد مصحوب بحكة (طفح جلدي على شكل خلايا النحل).</p><p dir="RTL">&bull;&nbsp; عسر هضم.</p><p dir="RTL">&bull;&nbsp; دوخة.</p><p dir="RTL">&bull;&nbsp; صداع.</p><p dir="RTL"><u>&nbsp;التأثيرات الجانبية الغير شائعة التي قد تظهرعند إجراء فحوصات الدم:</u></p><p dir="RTL">&bull;&nbsp; زيادة في إفراز بعض المواد (الإنزيمات) التي تفرز عن طريق الكبد.</p><p dir="RTL"><strong>&nbsp;</strong><strong>التأثيرات الجانبية النادرة</strong></p><p dir="RTL">&nbsp;قد تؤثر على ما يصل إلى شخص واحد من كل 1000 شخصاً</p><p dir="RTL">&bull;&nbsp; طفح جلدي، الذي قد يكون بصورة تقرحات، ويظهر على هيئة أقراص دائرية صغيرة (بقع داكنة في المركز محاطة بمنطقة شاحبة اللون مع وجود حلقة داكنة اللون حول الأطراف &ndash; حمامي متعددة الأشكال).</p><p dir="RTL">&sect;&nbsp; إذا لاحظت أياً من هذه الأعراض، يرجى منك التواصل مع الطبيب المعالج على الفور.</p><p dir="RTL"><u>&nbsp;</u><u>التأثيرات الجانبية النادرة التي قد تظهر عند إجراء فحوصات الدم:</u></p><p dir="RTL">&bull;&nbsp; نقص تعداد الخلايا المساهمة في عملية تجلط الدم.</p><p dir="RTL"><strong>&bull;&nbsp; </strong>نقص تعداد خلايا الدم البيضاء.</p><p dir="RTL"><strong>التأثيرات الجانبية الغير معروفة</strong></p><p dir="RTL">لا يمكن تقدير معدل تكرار حدوثها من البيانات المتاحة.</p><p dir="RTL">&bull;&nbsp; تفاعلات تحسسية (انظر أعلاه).</p><p dir="RTL">&bull;&nbsp; التهاب الأمعاء الغليظة (انظر أعلاه).</p><p dir="RTL">&bull;&nbsp; التهاب الغشاء الواقي المحيط بالدماغ (التهاب السحايا العقيم).</p><p dir="RTL">&bull;&nbsp; تفاعلات جلدية خطيرة بما في ذلك:</p><p dir="RTL">&sect;&nbsp;&nbsp; طفح جلدي منتشر على مساحة واسعة من الجلد مصحوباً بظهور تقرحات وتقشر الجلد، وبصفة خاصة حول الفم، الأنف، العينين والأعضاء التناسلية (متلازمة ستيفن- جونسن)، وقد يؤدي النوع الأكثر خطورة من هذا المرض إلى حدوث تقشر في مساحات واسعة من الجلد (أكثر من 30٪ من سطح الجسم- انحلال البشرة السمي التنخري).&nbsp;&nbsp;&nbsp;</p><p dir="RTL">&sect;&nbsp;&nbsp; طفح جلدي منتشر على مساحات واسعة من جلد أحمراللون مصحوباً بظهور بثورصغيرة متقيحة (التهاب الجلد التقشري الفقاعي).</p><p dir="RTL">&sect;&nbsp;&nbsp; طفح جلدي أحمر اللون متقشر مصحوباً بظهور نتوءات تحت الجلد وتقرحات (الطفح البثري).</p><p dir="RTL">&sect;&nbsp;&nbsp; أعراض شبيهة بأعراض الإنفلونزا مصحوباً بحدوث طفح جلدي، حمى، تورم الغدد وفحوصات دم غير طبيعية (بما في ذلك ارتفاع تعداد خلايا الدم البيضاء (كثرة الإيوزينات&nbsp;) وإنزيمات الكبد) (الإرتكاس الدوائي&nbsp;مع&nbsp;كثرة الإيوزينات&nbsp;والعلامات الجهازية)</p><p dir="RTL"><strong>&nbsp;يرجى منك التواصل مع الطبيب المعالج على الفور إذا تعرض الطفل لأياً من هذه الأعراض.</strong></p><p dir="RTL">&bull;&nbsp; التهاب الكبد (الالتهاب الكبدي).</p><p dir="RTL">&bull;&nbsp; يرقان، والناجم عن زيادة نسبة البليروبين في الدم (مادة تفرز في الكبد) والذي قد يؤدي إلى اصفرار لون الجلد وبياض العينين.</p><p dir="RTL">&bull;&nbsp; التهاب الأنابيب الكلوية.</p><p dir="RTL">&bull;&nbsp; زيادة الفترة الزمنية اللازمة لتجلط الدم.</p><p dir="RTL">&bull;&nbsp; فرط النشاط.</p><p dir="RTL">&bull;&nbsp; اختلاجات (لدى المرضى الذين يتناولون جرعات عالية من <strong>جلمنتين</strong> أو الذين يعانون من مشاكل في الكلى).</p><p dir="RTL">&bull;&nbsp; لسان مشعر أسود اللون.</p><p dir="RTL">&bull;&nbsp; تلون الأسنان (لدى الأطفال)، عادةً يختفي بعد غسل الأسنان بالفرشاة.</p><p dir="RTL"><u>التأثيرات الجانبية التي قد تظهر عند إجراء فحوصات الدم أو البول:</u></p><p dir="RTL">&bull;&nbsp; نقص شديد في تعداد خلايا الدم البيضاء.</p><p dir="RTL">&bull;&nbsp; نقص تعداد خلايا الدم الحمراء (فقر الدم الإنحلالي).</p><p dir="RTL">&bull;&nbsp; ظهور بلورات في البول.</p><p dir="RTL"><strong><u>الإبلاغ عن التأثيرات الجانبية</u></strong></p><p dir="RTL">يرجى منك إخبار طبيبك المعالج أو الصيدلي الذي تتعامل معه، في حال حدوث أياً من التأثيرات الجانبية بما في ذلك أية تأثيرات جانبية يحتمل حدوثها ولم يتم ذكرها في هذه النشرة. كما يمكنك الإبلاغ عن التأثيرات الجانبية مباشرة عن طريق:</p><p dir="RTL"><strong>&sect;&nbsp;&nbsp; </strong>&nbsp;<strong>المملكة العربية السعودية:</strong></p><p dir="RTL"><strong>المركز الوطني للتيقظ الدوائي:</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp; <strong>مركز الاتصال الموحد:</strong> 19999</p><p dir="RTL">-&nbsp;&nbsp;&nbsp; <strong>البريد الإلكتروني:</strong>&nbsp; npc.drug@sfda.gov.sa</p><p dir="RTL">-&nbsp;&nbsp;&nbsp; ا<strong>لموقع الإلكتروني:</strong> /https://ade.sfda.gov.sa</p><p dir="RTL">&sect;&nbsp;&nbsp; <strong>دول الخليج العربي الأخرى:</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;الرجاء الاتصال بجهات الوطنية في كل دولة.</p><p dir="RTL">إن تسجيل التأثيرات الجانبية يساعد في توفير المزيد من المعلومات حول سلامة هذا الدواء.</p><p dir="RTL"><strong>&nbsp;</strong></p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&bull;&nbsp; يحفظ بعيداً عن متناول ومرأى الأطفال.</p><p dir="RTL">&bull;&nbsp; &nbsp;يجب عدم إعطاء <strong>جلمنتين</strong> بعد تاريخ انتهاء الصلاحية المذكورعلى العبوة والملصق الداخلي للزجاجة.</p><p dir="RTL">&bull;&nbsp; &nbsp;قبل التحضير، يحفظ في درجة حرارة أقل من 30&deg;م، في مكان جاف، بعيداً عن الضوء.</p><p dir="RTL">&bull;&nbsp; بعد التحضير، يحفظ في الثلاجة (2-8&deg;م) ويستخدم خلال 7 أيام. رج الزجاجة جيداً قبل الاستعمال.</p><p dir="RTL">&bull;&nbsp; &nbsp;يجب عدم إعطاء <strong>جلمنتين</strong> إذا لاحظت وجود أي علامات تلف واضحة.</p><p dir="RTL">&bull;&nbsp; &nbsp;يجب عدم التخلص من الأدوية عبر المياه المبتذلة (مياه الصرف الصحي) أو النفايات المنزلية. اسأل الصيدلي الذي تتعامل معه عن كيفية &nbsp;&nbsp;التخلص من الأدوية التي لم تعد بحاجة إليها. ستساعد هذه الإجراءات على حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>ماهي محتويات </strong><strong>جلمنتين</strong></p><p dir="RTL"><strong><u>&nbsp;معلق جلمنتين 156 ملغم</u></strong></p><p dir="RTL">تحتوي كل ملعقة صغيرة (5 ملليلتر) من المعلق بعد التحضير على:</p><p dir="RTL">المواد الفعالة: أموكسيسيلين ثلاثي الهيدرات بما يعادل 125 ملغم من أموكسيسيلين وكلافيولانات البوتاسيوم بما يعادل 31,25 ملغم من حمض كلافيولانيك.</p><p dir="RTL">المواد غير الفعالة: حمض الستريك اللامائي، سترات الصوديوم، بنزوات الصوديوم، سليلوز دقيق البلورات، صمغ الزانثان، ثنائي أكسيد السيليكون الغروي، سكارين الصوديوم، نكهة الفراولة ومانيتول.</p><p dir="RTL"><strong><u>معلق جلمنتين فورت 312 ملغم</u></strong></p><p dir="RTL">تحتوي كل ملعقة صغيرة (5 ملليلتر) من المعلق بعد التحضير على:</p><p dir="RTL">المواد الفعالة: أموكسيسيلين ثلاثي الهيدرات بما يعادل 250 ملغم من أموكسيسيلين وكلافيولانات البوتاسيوم بما يعادل 62,5 ملغم من حمض كلافيولانيك.</p><p dir="RTL">المواد غير الفعالة: حمض الستريك اللامائي، سترات الصوديوم، بنزوات الصوديوم، سليلوز دقيق البلورات، صمغ الزانثان، ثنائي أكسيد السيليكون الغروي، سكارين الصوديوم، نكهة الكرز البري ومانيتول.&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p>يتوفر مسحوق <strong>جلمنتين</strong> و<strong>جلمنتين فورت</strong> لتحضير معلق فموي في عبوات تحتوي كلاً منها على زجاجة واحدة (سعة 100 ملليلتر بعد التحضير) مع ملعقة معيارية.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p>&quot;الخليج للصناعات الدوائية &quot; جلفار</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            28/3/2022م
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Julmentin 156mg/5mL Powder for Oral Suspension
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each teaspoonful (5mL) of the reconstituted suspension contains:
Item No.	Material Name	Scale (mg/5mL)
		
	Active Ingredients	
1.		Amoxicillin Trihydrate 
(Equivalent to Amoxicillin 125mg)	144.00
2.		Potassium Clavulanic 
(Potassium Clavulanic mixture 75mg, 
1:1 with Avicel PH 112)
(Equivalent to Clavulanic Acid 31.25mg)	37.500
		
	Inactive Ingredients	
1.		Citric acid, anhydrous	2.167
2.		Sodium citrate	8.335
3.		Sodium benzoate	2.085
4.		Microcrystalline cellulose	33.100
5.		Xanthan gum	8.750
6.		Colloidal silicon dioxide	10.883
7.		Strawberry dry flavour	10.000
8.		Saccharin sodium	5.500
9.		Mannitol	950.430

For a full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                
Powder for reconstitution for oral suspension
Description: White to yellowish-white powder.


            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Julmentin</strong> is indicated for the treatment of the following infections in adults and children (see sections 4.2, 4.4 and 5.1):</p><p>&sect; Acute bacterial sinusitis (adequately diagnosed)</p><p>&sect; Acute otitis media</p><p>&sect; Acute exacerbations of chronic bronchitis (adequately diagnosed)</p><p>&sect; Community acquired pneumonia</p><p>&sect; Cystitis</p><p>&sect; Pyelonephritis</p><p>&sect; Skin and soft tissue infections in particular cellulitis, animal bites, severe dental abscess with spreading cellulitis</p><p>&sect; Bone and joint infections, in particular osteomyelitis.</p><p>Consideration should be given to official guidance on the appropriate use of antibacterial agents</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><u>Posology</u></strong></p><p>Doses are expressed throughout in terms of amoxicillin/clavulanic acid content except when doses are stated in terms of an individual component.</p><p>The dose of <strong>Julmentin</strong> that is selected to treat an individual infection should take into account:</p><p>&sect; The expected pathogens and their likely susceptibility to antibacterial agents (see section 4.4)</p><p>&sect; The severity and the site of the infection</p><p>&sect; The age, weight and renal function of the patient as shown below.</p><p>The use of alternative presentations of amoxicillin/clavulanic acid (e.g. those that provide higher doses of amoxicillin and/or different ratios of amoxicillin to clavulanic acid) should be considered as necessary (see sections 4.4 and 5.1).&nbsp;</p><p>For children &lt; 40 kg, this formulation of amoxicillin/clavulanic acid provides a maximum daily dose of 2400 mg amoxicillin/600 mg clavulanic acid, when administered as recommended below. If it is considered that a higher daily dose of amoxicillin is required, it is recommended that another preparation of amoxicillin/clavulanic acid is selected in order to avoid administration of unnecessarily high daily doses of clavulanic acid (see sections 4.4 and 5.1).</p><p>The duration of therapy should be determined by the response of the patient. Some infections (e.g. osteomyelitis) require longer periods of treatment. Treatment should not be extended beyond 14 days without review (see section 4.4 regarding prolonged therapy).</p><p><strong><u>Adults and children &ge; 40 kg</u></strong></p><p>Adults and children &ge; 40 kg should be treated with the adult formulations of <strong>Julmentin</strong>.</p><p><strong><u>Children &lt; 40 kg</u></strong></p><p>Lower dose: 20 mg/5 mg/kg/day to 40 mg/10 mg/kg/day given in three divided doses.</p><p>Higher dose: 40 mg/10 mg/kg/day to 60 mg/15 mg/kg/day given in three divided doses.</p><p><img alt="" src="data:image/png;base64,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" /></p><p>NR - Not recommended. No clinical data are available on doses of amoxicillin/clavulanic acid 4:1 formulations higher than 40 mg/10 mg/kg per day in children under 2 years.</p><p>Alternative oral formulations of <strong>Julmentin</strong> should be considered to deliver practical dose recommendations.</p><p>Children may be treated with <strong>Julmentin</strong> tablets, or suspensions. Children aged 6 years and below should preferably be treated with <strong>Julmentin</strong> suspension.</p><p>The dose (ml) to be given to the patient three times daily can also be calculated using the following formula below:</p><p><!--[if gte vml 1]><v:shapetype id="_x0000_t75" coordsize="21600,21600"
 o:spt="75" o:preferrelative="t" path="m@4@5l@4@11@9@11@9@5xe" filled="f"
 stroked="f">
 <v:stroke joinstyle="miter"/>
 <v:formulas>
  <v:f eqn="if lineDrawn pixelLineWidth 0"/>
  <v:f eqn="sum @0 1 0"/>
  <v:f eqn="sum 0 0 @1"/>
  <v:f eqn="prod @2 1 2"/>
  <v:f eqn="prod @3 21600 pixelWidth"/>
  <v:f eqn="prod @3 21600 pixelHeight"/>
  <v:f eqn="sum @0 0 1"/>
  <v:f eqn="prod @6 1 2"/>
  <v:f eqn="prod @7 21600 pixelWidth"/>
  <v:f eqn="sum @8 21600 0"/>
  <v:f eqn="prod @7 21600 pixelHeight"/>
  <v:f eqn="sum @10 21600 0"/>
 </v:formulas>
 <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
 <o:lock v:ext="edit" aspectratio="t"/>
</v:shapetype><v:shape id="Picture_x0020_1" o:spid="_x0000_i1025" type="#_x0000_t75"
 style='width:397.5pt;height:36.75pt;visibility:visible'>
 <v:imagedata src="file:///C:/Users/ghofranj/AppData/Local/Temp/msohtmlclip1/01/clip_image001.png"
  o:title=""/>
</v:shape><![endif]--><!--[if gte vml 1]><v:shapetype id="_x0000_t75" coordsize="21600,21600"
 o:spt="75" o:preferrelative="t" path="m@4@5l@4@11@9@11@9@5xe" filled="f"
 stroked="f">
 <v:stroke joinstyle="miter"/>
 <v:formulas>
  <v:f eqn="if lineDrawn pixelLineWidth 0"/>
  <v:f eqn="sum @0 1 0"/>
  <v:f eqn="sum 0 0 @1"/>
  <v:f eqn="prod @2 1 2"/>
  <v:f eqn="prod @3 21600 pixelWidth"/>
  <v:f eqn="prod @3 21600 pixelHeight"/>
  <v:f eqn="sum @0 0 1"/>
  <v:f eqn="prod @6 1 2"/>
  <v:f eqn="prod @7 21600 pixelWidth"/>
  <v:f eqn="sum @8 21600 0"/>
  <v:f eqn="prod @7 21600 pixelHeight"/>
  <v:f eqn="sum @10 21600 0"/>
 </v:formulas>
 <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
 <o:lock v:ext="edit" aspectratio="t"/>
</v:shapetype><v:shape id="Picture_x0020_1" o:spid="_x0000_i1025" type="#_x0000_t75"
 style='width:397.5pt;height:36.75pt;visibility:visible'>
 <v:imagedata src="file:///C:/Users/ghofranj/AppData/Local/Temp/msohtmlclip1/01/clip_image001.png"
  o:title=""/>
</v:shape><![endif]--><img width="530" height="49" alt="" vspace="0" hspace="0" border="0" style="width:530px;height:49px;margin-top:0px;margin-bottom:0px;margin-left:0px;margin-right:0px;border:0px solid black;" src="file:///C:/Users/ghofranj/AppData/Local/Temp/msohtmlclip1/01/clip_image002.jpg" /></p><p>* Only consideration of the amoxicillin component is required for this calculation.</p><p>For example, a 6 kg child treated at 20 mg/5 mg/kg/day:</p><p><!--[if gte vml 1]><v:shapetype id="_x0000_t75" coordsize="21600,21600"
 o:spt="75" o:preferrelative="t" path="m@4@5l@4@11@9@11@9@5xe" filled="f"
 stroked="f">
 <v:stroke joinstyle="miter"/>
 <v:formulas>
  <v:f eqn="if lineDrawn pixelLineWidth 0"/>
  <v:f eqn="sum @0 1 0"/>
  <v:f eqn="sum 0 0 @1"/>
  <v:f eqn="prod @2 1 2"/>
  <v:f eqn="prod @3 21600 pixelWidth"/>
  <v:f eqn="prod @3 21600 pixelHeight"/>
  <v:f eqn="sum @0 0 1"/>
  <v:f eqn="prod @6 1 2"/>
  <v:f eqn="prod @7 21600 pixelWidth"/>
  <v:f eqn="sum @8 21600 0"/>
  <v:f eqn="prod @7 21600 pixelHeight"/>
  <v:f eqn="sum @10 21600 0"/>
 </v:formulas>
 <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
 <o:lock v:ext="edit" aspectratio="t"/>
</v:shapetype><v:shape id="Picture_x0020_1" o:spid="_x0000_i1025" type="#_x0000_t75"
 style='width:238.5pt;height:139.5pt;visibility:visible'>
 <v:imagedata src="file:///C:/Users/ghofranj/AppData/Local/Temp/msohtmlclip1/01/clip_image001.png"
  o:title=""/>
</v:shape><![endif]--><img width="318" height="186" alt="" vspace="0" hspace="0" border="0" style="width:318px;height:186px;margin-top:0px;margin-bottom:0px;margin-left:0px;margin-right:0px;border:0px solid black;" src="file:///C:/Users/ghofranj/AppData/Local/Temp/msohtmlclip1/01/clip_image002.jpg" /></p><p><!--[if gte vml 1]><v:shape id="_x0000_i1026"
 type="#_x0000_t75" style='width:238.5pt;height:139.5pt;visibility:visible'>
 <v:imagedata src="file:///C:/Users/ghofranj/AppData/Local/Packages/oice_16_974fa576_32c1d314_3805/AC/Temp/msohtmlclip1/01/clip_image005.png"
  o:title=""/>
</v:shape><![endif]--></p><p>&nbsp;</p><p><strong><u>Elderly </u></strong></p><p>No dose adjustment is considered necessary. Elderly patients should be treated with adult formulations of <strong>Julmentin</strong>.</p><p><strong><u>Renal impairment</u></strong></p><p>Dose adjustments are based on the maximum recommended level of amoxicillin.</p><p>No adjustment in dose is required in patients with creatinine clearance (CrCl) greater than 30 ml/min.</p><p><strong><em>Children &lt; 40 kg</em></strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:542px"><tbody><tr><td style="vertical-align:top"><p>CrCl: 10-30 ml/min</p></td><td style="vertical-align:top"><p>15 mg/3.75mg/kg twice daily (maximum 500 mg/125 mg twice daily).</p></td></tr><tr><td style="vertical-align:top"><p>CrCl &lt; 10 ml /min</p></td><td style="vertical-align:top"><p>15 mg/3.75mg/kg as a single daily dose (maximum 500 mg/125 mg).</p></td></tr><tr><td style="vertical-align:top"><p>Haemodialysis</p></td><td style="vertical-align:top"><p>15 mg/3.75 mg/kg per day once daily.</p><p>Prior to haemodialysis 15mg/3.75 mg/kg. In order to restore circulating drug levels, 15mg/3.75 mg per kg should be administered after haemodialysis.</p></td></tr></tbody></table><p><strong><u>Hepatic impairment</u></strong></p><p>Dose with caution and monitor hepatic function at regular intervals (see sections 4.3 and 4.4).</p><p><strong><u>Method of administration</u></strong></p><p><strong>Julmentin</strong> is for oral use.</p><p>Administer at the start of a meal to minimise potential gastrointestinal intolerance and optimise absorption of amoxicillin/clavulanic acid.</p><p>Therapy can be started parenterally according the SmPC of the IV-formulation and continued with an oral preparation.</p><p>Shake to loosen powder, add water as directed, invert and shake.</p><p>Shake the bottle before each dose (see section 6.6).</p><p>For instructions on reconstitution of the medicinal product before administration, see section 6.6.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                
	Hypersensitivity to the active substances, to any of the penicillins or to any of the excipients listed in section 6.1.
	History of a severe immediate hypersensitivity reaction (e.g. anaphylaxis) to another beta-lactam agent (e.g. a cephalosporin, carbapenem or monobactam).
	History of jaundice/hepatic impairment due to amoxicillin/clavulanic acid (see section 4.8).

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Before initiating therapy with amoxicillin/clavulanic acid, careful enquiry should be made concerning previous hypersensitivity reactions to penicillins, cephalosporins or other beta-lactam agents (see sections 4.3 and 4.8).</p><p>Serious and occasionally fatal hypersensitivity (anaphylactoid) reactions have been reported in patients on penicillin therapy. These reactions are more likely to occur in individuals with a history of penicillin hypersensitivity and in atopic individuals. If an allergic reaction occurs, amoxicillin/clavulanic acid therapy must be discontinued and appropriate alternative therapy instituted.</p><p>In the case that an infection is proven to be due to an amoxicillin-susceptible organisms(s) then consideration should be given to switching from amoxicillin/clavulanic acid to amoxicillin in accordance with official guidance.</p><p>This presentation of amoxicillin/clavulanic acid is not suitable for use when there is a high risk that the presumptive pathogens have reduced susceptibility or resistance to beta-lactam agents that is not mediated by beta-lactamases susceptible to inhibition by clavulanic acid. This presentation should not be used to treat penicillin-resistant&nbsp;<em>S. pneumoniae</em>.</p><p>Convulsions may occur in patients with impaired renal function or in those receiving high doses (see section 4.8).</p><p>Amoxicillin/clavulanic acid should be avoided if infectious mononucleosis is suspected since the occurrence of a morbilliform rash has been associated with this condition following the use of amoxicillin.</p><p>Concomitant use of allopurinol during treatment with amoxicillin can increase the likelihood of allergic skin reactions.</p><p>Prolonged use may occasionally result in overgrowth of non-susceptible organisms.</p><p>The occurrence at the treatment initiation of a feverish generalised erythema associated with pustula may be a symptom of acute generalised exanthemous pustulosis (AGEP) (see Section 4.8). This reaction requires amoxicillin/clavulanic acid discontinuation and contraindicates any subsequent administration of amoxicillin.</p><p>Amoxicillin/clavulanic acid should be used with caution in patients with evidence of hepatic impairment (see sections 4.2, 4.3 and 4.8).</p><p>Hepatic events have been reported predominantly in males and elderly patients and may be associated with prolonged treatment. These events have been very rarely reported in children. In all populations, signs and symptoms usually occur during or shortly after treatment but in some cases may not become apparent until several weeks after treatment has ceased. These are usually reversible. Hepatic events may be severe and, in extremely rare circumstances, deaths have been reported. These have almost always occurred in patients with serious underlying disease or taking concomitant medications known to have the potential for hepatic effects (see section 4.8).</p><p>Antibiotic-associated colitis has been reported with nearly all antibacterial agents including amoxicillin and may range in severity from mild to life threatening (see section 4.8). Therefore, it is important to consider this diagnosis in patients who present with diarrhoea during or subsequent to the administration of any antibiotics. Should antibiotic-associated colitis occur, amoxicillin/clavulanic acid should immediately be discontinued, a physician be consulted and an appropriate therapy initiated. Anti-peristaltic medicinal products are contraindicated in this situation.</p><p>Periodic assessment of organ system functions; including renal, hepatic and haematopoietic function is advisable during prolonged therapy.</p><p>Prolongation of prothrombin time has been reported rarely in patients receiving amoxicillin/clavulanic acid. Appropriate monitoring should be undertaken when anticoagulants are prescribed concomitantly. Adjustments in the dose of oral anticoagulants may be necessary to maintain the desired level of anticoagulation (see sections 4.5 and 4.8).</p><p>In patients with renal impairment, the dose should be adjusted according to the degree of impairment (see section 4.2).</p><p>In patients with reduced urine output, crystalluria has been observed very rarely, predominantly with parenteral therapy. During the administration of high doses of amoxicillin, it is advisable to maintain adequate fluid intake and urinary output in order to reduce the possibility of amoxicillin crystalluria. In patients with bladder catheters, a regular check of patency should be maintained (see section 4.9).</p><p>During treatment with amoxicillin, enzymatic glucose oxidase methods should be used whenever testing for the presence of glucose in urine because false positive results may occur with non-enzymatic methods.</p><p>The presence of clavulanic acid in amoxicillin/clavulanic acid may cause a non-specific binding of IgG and albumin by red cell membranes leading to a false positive Coombs test.</p><p>There have been reports of positive test results using the Bio-Rad Laboratories Platelia&nbsp;<em>Aspergillus</em>&nbsp;EIA test in patients receiving amoxicillin/clavulanic acid who were subsequently found to be free of&nbsp;<em>Aspergillus</em>&nbsp;infection. Cross-reactions with non-<em>Aspergillus</em>&nbsp;polysaccharides and polyfuranoses with Bio-Rad Laboratories Platelia&nbsp;<em>Aspergillus</em>&nbsp;EIA test have been reported. Therefore, positive test results in patients receiving amoxicillin/clavulanic acid should be interpreted cautiously and confirmed by other diagnostic methods.</p><p>This medicinal product contains saccharin. Patients with rare glucose-galactose malabsorption should not take this medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><u>Oral anticoagulants</u></strong></p><p>Oral anticoagulants and penicillin antibiotics have been widely used in practice without reports of interaction. However, in the literature there are cases of increased international normalised ratio in patients maintained on acenocoumarol or warfarin and prescribed a course of amoxicillin. If co-administration is necessary, the prothrombin time or international normalised ratio should be carefully monitored with the addition or withdrawal of amoxicillin. Moreover, adjustments in the dose of oral anticoagulants may be necessary (see sections 4.4 and 4.8).</p><p><strong><u>Methotrexate</u></strong></p><p>Penicillins may reduce the excretion of methotrexate causing a potential increase in toxicity.</p><p><strong><u>Probenecid</u></strong></p><p>Concomitant use of probenecid is not recommended. Probenecid decreases the renal tubular secretion of amoxicillin. Concomitant use of probenecid may result in increased and prolonged blood levels of amoxicillin but not of clavulanic acid.</p><p><strong><u>Mycophenolate mofetil</u></strong></p><p>In patients receiving mycophenolate mofetil, reduction in pre-dose concentration of the active metabolite mycophenolic acid (MPA) of approximately 50% has been reported following commencement of oral amoxicillin plus clavulanic acid. The change in pre-dose level may not accurately represent changes in overall MPA exposure. Therefore, a change in the dose of mycophenolate mofetil should not normally be necessary in the absence of clinical evidence of graft dysfunction. However, close clinical monitoring should be performed during the combination and shortly after antibiotic treatment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><u>Pregnancy</u></strong></p><p>Animal studies do not indicate direct or indirect harmful effects with respect to pregnancy, embryonal/foetal development, parturition or postnatal development (see section 5.3). Limited data on the use of amoxicillin/clavulanic acid during pregnancy in humans do not indicate an increased risk of congenital malformations. In a single study in women with preterm, premature rupture of the foetal membrane it was reported that prophylactic treatment with amoxicillin/clavulanic acid may be associated with an increased risk of necrotising enterocolitis in neonates. Use should be avoided during pregnancy, unless considered essential by the physician.</p><p><strong><u>Breastfeeding</u></strong></p><p>Both substances are excreted into breast milk (nothing is known of the effects of clavulanic acid on the breast-fed infant). Consequently, diarrhoea and fungus infection of the mucous membranes are possible in the breast-fed infant, so that breast-feeding might have to be discontinued. The possibility of sensitisation should be taken into account. Amoxicillin/clavulanic acid should only be used during breast-feeding after benefit/risk assessment by the physician in charge</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No studies on the effects on the ability to drive and use machines have been performed. However, undesirable effects may occur (e.g. allergic reactions, dizziness, convulsions), which may influence the ability to drive and use machines (see section 4.8).</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The most commonly reported adverse drug reactions (ADRs) are diarrhoea, nausea and vomiting.</p><p>The ADRs derived from clinical studies and post-marketing surveillance with amoxicillin/clavulanic acid, sorted by MedDRA System Organ Class are listed below.</p><p>The following terminologies have been used in order to classify the occurrence of undesirable effects.</p><p>&nbsp;</p><p>Very common (&ge;1/10)</p><p>Common (&ge;1/100 to &lt;1/10)</p><p>Uncommon (&ge;1/1,000 to &lt;1/100)</p><p>Rare (&ge;1/10,000 to &lt;1/1,000)</p><p>Very rare (&lt;1/10,000)</p><p>Not known (cannot be estimated from the available data)</p><table border="1" cellspacing="0" cellpadding="0" style="width:536px"><tbody><tr><td colspan="2" style="vertical-align:top"><p><u>Infections and infestations</u></p></td></tr><tr><td style="vertical-align:top"><p>Mucocutaneous candidosis</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Overgrowth of non-susceptible organisms</p></td><td style="vertical-align:top"><p>Not known</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><u>Blood and lymphatic system disorders</u></p></td></tr><tr><td style="vertical-align:top"><p>Reversible leucopenia (including neutropenia)</p></td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td style="vertical-align:top"><p>Thrombocytopenia</p></td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td style="vertical-align:top"><p>Reversible agranulocytosis</p></td><td style="vertical-align:top"><p>Not known</p></td></tr><tr><td style="vertical-align:top"><p>Haemolytic anaemia</p></td><td style="vertical-align:top"><p>Not known</p></td></tr><tr><td style="vertical-align:top"><p>Prolongation of bleeding time and prothrombin time<sup>1</sup></p></td><td style="vertical-align:top"><p>Not known</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><u>Immune system disorders</u><sup>10</sup></p></td></tr><tr><td style="vertical-align:top"><p>Angioneurotic oedema</p></td><td style="vertical-align:top"><p>Not known</p></td></tr><tr><td style="vertical-align:top"><p>Anaphylaxis</p></td><td style="vertical-align:top"><p>Not known</p></td></tr><tr><td style="vertical-align:top"><p>Serum sickness-like syndrome</p></td><td style="vertical-align:top"><p>Not known</p></td></tr><tr><td style="vertical-align:top"><p>Hypersensitivity vasculitis</p></td><td style="vertical-align:top"><p>Not known</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><u>Nervous system disorders</u></p></td></tr><tr><td style="vertical-align:top"><p>Dizziness</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Headache</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Reversible hyperactivity</p></td><td style="vertical-align:top"><p>Not known</p></td></tr><tr><td style="vertical-align:top"><p>Convulsions<sup>2</sup></p></td><td style="vertical-align:top"><p>Not known</p></td></tr><tr><td style="vertical-align:top"><p>Aeseptic meningitis</p></td><td style="vertical-align:top"><p>Not known</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><u>Gastrointestinal disorders</u></p></td></tr><tr><td style="vertical-align:top"><p>Diarrhoea</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Nausea<sup>3</sup></p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Vomiting</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Indigestion</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Antibiotic-associated colitis<sup>4</sup></p></td><td style="vertical-align:top"><p>Not known</p></td></tr><tr><td style="vertical-align:top"><p>Black hairy tongue</p></td><td style="vertical-align:top"><p>Not known</p></td></tr><tr><td style="vertical-align:top"><p>Tooth discolouration<sup>11</sup></p></td><td style="vertical-align:top"><p>Not known</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><u>Hepatobiliary disorders</u></p></td></tr><tr><td style="vertical-align:top"><p>Rises in AST and/or ALT<sup>5</sup></p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Hepatitis<sup>6</sup></p></td><td style="vertical-align:top"><p>Not known</p></td></tr><tr><td style="vertical-align:top"><p>Cholestatic jaundice<sup>6</sup></p></td><td style="vertical-align:top"><p>Not known</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><u>Skin and subcutaneous tissue disorders</u><sup>7</sup></p></td></tr><tr><td style="vertical-align:top"><p>Skin rash</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Pruritus</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Urticaria</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Erythema multiforme</p></td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td style="vertical-align:top"><p>Stevens-Johnson syndrome</p></td><td style="vertical-align:top"><p>Not known</p></td></tr><tr><td style="vertical-align:top"><p>Toxic epidermal necrolysis</p></td><td style="vertical-align:top"><p>Not known</p></td></tr><tr><td style="vertical-align:top"><p>Bullous exfoliative-dermatitis</p></td><td style="vertical-align:top"><p>Not known</p></td></tr><tr><td style="vertical-align:top"><p>Acute generalised exanthemous pustulosis (AGEP)<sup>9</sup></p></td><td style="vertical-align:top"><p>Not known</p></td></tr><tr><td style="vertical-align:top"><p>Drug reaction with eosinophilia and systemic symptoms (DRESS)</p></td><td style="vertical-align:top"><p>Not known</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><u>Renal and urinary disorders</u></p></td></tr><tr><td style="vertical-align:top"><p>Interstitial nephritis</p></td><td style="vertical-align:top"><p>Not known</p></td></tr><tr><td style="vertical-align:top"><p>Crystalluria<sup>8</sup></p></td><td style="vertical-align:top"><p>Not known</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><sup>1</sup>&nbsp;See section 4.4</p><p><sup>2</sup>&nbsp;See section 4.4</p><p><sup>3</sup>&nbsp;Nausea is more often associated with higher oral doses. If gastrointestinal reactions are evident, they may be reduced by taking amoxicillin/clavulanic clavulanic acid with meal.</p><p><sup>4&nbsp;</sup>Including pseudomembranous colitis and haemorrhagic colitis (see section 4.4)</p><p><sup>5</sup>&nbsp;A moderate rise in AST and/or ALT has been noted in patients treated with beta-lactam class antibiotics, but the significance of these findings is unknown.</p><p><sup>6&nbsp;</sup>These events have been noted with other penicillins and cephalosporins (see section 4.4).</p><p><sup>7</sup>&nbsp;If any hypersensitivity dermatitis reaction occurs, treatment should be discontinued (see section 4.4).</p><p><sup>8</sup>&nbsp;See section 4.9</p><p><sup>9</sup>&nbsp;See section 4.4</p><p><sup>10</sup>&nbsp;See sections 4.3 and 4.4</p><p><sup>11&nbsp;</sup>Superficial tooth discolouration has been reported very rarely in children. Good oral hygiene may help to prevent tooth discolouration as it can usually be removed by brushing.</p></td></tr></tbody></table><p><strong><u>&nbsp;</u></strong></p><p><strong><u>To report any side effect(s):</u></strong></p><p>&sect; <strong>Saudi Arabia:</strong></p><p>The National Pharmacovigilance Centre (NPC):</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SFDA Call Centre: 19999</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; E-mail: npc.drug@sfda.gov.sa</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Website: https://ade.sfda.gov.sa/</p><p>&sect; <strong>Other GCC States: </strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Please contact the relevant competent authority.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><u>Symptoms and signs of overdose</u></strong></p><p>Gastrointestinal symptoms and disturbance of the fluid and electrolyte balances may be evident. Amoxicillin crystalluria, in some cases leading to renal failure, has been observed (see section 4.4).</p><p>Convulsions may occur in patients with impaired renal function or in those receiving high doses.</p><p>Amoxicillin has been reported to precipitate in bladder catheters, predominantly after intravenous administration of large doses. A regular check of patency should be maintained (see section 4.4).</p><p><strong><u>Treatment of intoxication</u></strong></p><p>Gastrointestinal symptoms may be treated symptomatically, with attention to the water/electrolyte balance.</p><p>Amoxicillin/clavulanic acid can be removed from the circulation by haemodialysis.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Pharmacotherapeutic group:</strong> Combinations of penicillins, incl. beta-lactamase inhibitors; ATC code: J01CR02.</p><p><strong><u>Mechanism of action</u></strong></p><p>Amoxicillin is a semisynthetic penicillin (beta-lactam antibiotic) that inhibits one or more enzymes (often referred to as penicillin-binding proteins, PBPs) in the biosynthetic pathway of bacterial peptidoglycan, which is an integral structural component of the bacterial cell wall. Inhibition of peptidoglycan synthesis leads to weakening of the cell wall, which is usually followed by cell lysis and death.</p><p>Amoxicillin is susceptible to degradation by beta-lactamases produced by resistant bacteria and therefore the spectrum of activity of amoxicillin alone does not include organisms which produce these enzymes.</p><p>Clavulanic acid is a beta-lactam structurally related to penicillins. It inactivates some beta-lactamase enzymes thereby preventing inactivation of amoxicillin. Clavulanic acid alone does not exert a clinically useful antibacterial effect.</p><p><strong><u>Pharmacokinetic/pharmacodynamic relationship</u></strong></p><p>The time above the minimum inhibitory concentration (T&gt;MIC) is considered to be the major determinant of efficacy for amoxicillin.</p><p><strong><u>Mechanisms of resistance</u></strong></p><p>The two main mechanisms of resistance to amoxicillin/clavulanic acid are:</p><p>&sect; Inactivation by those bacterial beta-lactamases that are not themselves inhibited by clavulanic acid, including class B, C and D.</p><p>&sect; Alteration of PBPs, which reduce the affinity of the antibacterial agent for the target.</p><p>Impermeability of bacteria or efflux pump mechanisms may cause or contribute to bacterial resistance, particularly in Gram-negative bacteria.</p><p><strong><u>Breakpoints</u></strong></p><p>MIC breakpoints for amoxicillin/clavulanic acid are those of the European Committee on Antimicrobial Susceptibility Testing (EUCAST).</p><p><!--[if gte vml 1]><v:shapetype id="_x0000_t75" coordsize="21600,21600"
 o:spt="75" o:preferrelative="t" path="m@4@5l@4@11@9@11@9@5xe" filled="f"
 stroked="f">
 <v:stroke joinstyle="miter"/>
 <v:formulas>
  <v:f eqn="if lineDrawn pixelLineWidth 0"/>
  <v:f eqn="sum @0 1 0"/>
  <v:f eqn="sum 0 0 @1"/>
  <v:f eqn="prod @2 1 2"/>
  <v:f eqn="prod @3 21600 pixelWidth"/>
  <v:f eqn="prod @3 21600 pixelHeight"/>
  <v:f eqn="sum @0 0 1"/>
  <v:f eqn="prod @6 1 2"/>
  <v:f eqn="prod @7 21600 pixelWidth"/>
  <v:f eqn="sum @8 21600 0"/>
  <v:f eqn="prod @7 21600 pixelHeight"/>
  <v:f eqn="sum @10 21600 0"/>
 </v:formulas>
 <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
 <o:lock v:ext="edit" aspectratio="t"/>
</v:shapetype><v:shape id="Picture_x0020_1" o:spid="_x0000_i1025" type="#_x0000_t75"
 style='width:225pt;height:2in;visibility:visible'>
 <v:imagedata src="file:///C:/Users/ghofranj/AppData/Local/Temp/msohtmlclip1/01/clip_image001.png"
  o:title=""/>
</v:shape><![endif]--><img width="300" height="192" src="file:///C:/Users/ghofranj/AppData/Local/Temp/msohtmlclip1/01/clip_image002.jpg" /></p><p><sup>1</sup>For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/l.</p><p><sup>2a</sup>Breakpoint values in the table are based on benzylpenicillin breakpoints. The susceptibility is inferred from the</p><p>benzylpenicillin susceptibility.</p><p><sup>2b</sup>The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.</p><p><sup>3a</sup>Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Staphylococci that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Staphylococci that test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to beta-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Staphylococci that test resistant to cefoxitin are resistant to all penicillins.</p><p><sup>3b</sup>Most coagulase-negative staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and</p><p>ticarcillin. No currently available method can reliably detect penicillinase production in coagulase-negative staphylococci but methicillin resistance can be detected with cefoxitin as described.</p><p><sup>4</sup>Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).</p><p><sup>5 </sup>Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in E. faecalis (confirm with MIC) but common in E. faecium.</p><p><sup>6</sup>The oxacillin 1 &mu;g disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone &ge;20 mm, or benzylpenicillin MIC &le;0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, can be reported susceptible without further testing.</p><p><sup>7 </sup>Aminopenicillin breakpoints in enterococci are based on intravenous administration. Oral administration is relevant for urinary tract infections only.</p><p><sup>8</sup>The addition of a beta-lactamase inhibitor does not add clinical benefit.</p><p><sup>9</sup>Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed. Isolates categorised as screen positive should be tested for susceptibility to individual agents. For benzylpenicillin screen negative isolates (MIC &le;0.25 mg/L), susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin, screen positive isolates (MIC &gt;0.25 mg/L), susceptibility is inferred from ampicillin</p><p>The prevalence of resistance may vary geographically and with time for selected species, and local information on resistance is desirable, particularly when treating severe infections. As necessary, expert advice should be sought when the local prevalence of resistance is such that the utility of the agent in at least some types of infections is questionable.</p><table border="1" cellspacing="0" cellpadding="0" style="width:536px"><tbody><tr><td style="vertical-align:top"><p><u>Commonly susceptible species</u></p></td></tr><tr><td style="vertical-align:top"><p><u>Aerobic Gram-positive micro-organisms</u></p><p><em>Enterococcus faecalis</em></p><p><em>Gardnerella vaginalis</em></p><p><em>Staphylococcus aureus (</em>methicillin-susceptible)&pound;</p><p>Coagulase-negative staphylococci (methicillin-susceptible)</p><p><em>Streptococcus agalactiae</em></p><p><em>Streptococcus pneumoniae</em><sup>1</sup></p><p><em>Streptococcus pyogenes</em>&nbsp;and other beta-haemolytic streptococci</p><p><em>Streptococcus viridans&nbsp;</em>group</p><p><u>Aerobic Gram-negative micro-organisms</u></p><p><em>Capnocytophaga&nbsp;</em>spp.</p><p><em>Eikenella corrodens</em></p><p><em>Haemophilus influenzae</em><sup>2</sup></p><p><em>Moraxella catarrhalis</em></p><p><em>Pasteurella multocida</em></p><p><u>Anaerobic micro-organisms</u></p><p><em>Bacteroides fragilis</em></p><p><em>Fusobacterium nucleatum</em></p><p><em>Prevotella</em>&nbsp;spp.</p></td></tr><tr><td style="vertical-align:top"><p><u>Species for which acquired resistance may be a problem</u></p></td></tr><tr><td style="vertical-align:top"><p><u>Aerobic Gram-positive micro-organisms</u></p><p><em>Enterococcus faecium&nbsp;</em>$</p><p><u>Aerobic Gram-negative micro-organisms</u></p><p><em>Escherichia coli</em></p><p><em>Klebsiella oxytoca</em></p><p><em>Klebsiella pneumoniae</em></p><p><em>Proteus mirabilis</em></p><p><em>Proteus vulgaris</em></p></td></tr><tr><td style="vertical-align:top"><p><u>Inherently resistant organisms</u></p></td></tr><tr><td style="vertical-align:top"><p><u>Aerobic Gram-negative micro-organisms</u></p><p><em>Acinetobacter&nbsp;</em>sp.</p><p><em>Citrobacter freundii</em></p><p><em>Enterobacter</em>&nbsp;sp.</p><p><em>Legionella pneumophila</em></p><p><em>Morganella morganii</em></p><p><em>Providencia&nbsp;</em>spp.</p><p><em>Pseudomonas&nbsp;</em>sp.</p><p><em>Serratia&nbsp;</em>sp.</p><p><em>Stenotrophomonas maltophilia</em></p><p><u>Other micro-organisms</u></p><p><em>Chlamydophila pneumoniae</em></p><p><em>Chlamydophila psittaci</em></p><p><em>Coxiella burnetti</em></p><p><em>Mycoplasma pneumoniae</em></p></td></tr><tr><td style="vertical-align:top"><p>$ Natural intermediate susceptibility in the absence of acquired mechanism of resistance.</p><p>&pound;All methicillin-resistant staphylococci are resistant to amoxicillin/clavulanic acid</p><p><sup>1</sup><em>Streptococcus pneumoniae</em>&nbsp;that are resistant to penicillin should not be treated with this presentation of amoxicillin/clavulanic acid (see sections 4.2 and 4.4).</p><p><sup>2&nbsp;</sup>Strains with decreased susceptibility have been reported in some countries in the EU with a frequency higher than 10%.</p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><u>Absorption</u></strong></p><p>Amoxicillin and clavulanic acid, are fully dissociated in aqueous solution at physiological pH. Both components are rapidly and well absorbed by the oral route of administration. Following oral administration, amoxicillin and clavulanic acid are approximately 70% bioavailable. The plasma profiles of both components are similar and the time to peak plasma concentration (T<sub>max</sub>) in each case is approximately one hour. The pharmacokinetic results for a study, in which amoxicillin/clavulanic acid (500 mg/125 mg tablets three times daily) was administered in the fasting state to groups of healthy volunteers are presented below.</p><table border="1" cellspacing="0" cellpadding="0" style="width:516px"><tbody><tr><td colspan="6" style="vertical-align:top"><p>Mean (&plusmn; SD) pharmacokinetic parameters</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Active substance(s) administered</p></td><td style="vertical-align:top"><p>Dose</p></td><td style="vertical-align:top"><p>C<sub>max</sub></p></td><td style="vertical-align:top"><p>T<sub>max&nbsp;</sub>*</p></td><td style="vertical-align:top"><p>AUC&nbsp;<sub>(0-24h)</sub></p></td><td style="vertical-align:top"><p>T 1/2</p></td></tr><tr><td style="vertical-align:top"><p>(mg)</p></td><td style="vertical-align:top"><p>(&mu;g/ml)</p></td><td style="vertical-align:top"><p>(h)</p></td><td style="vertical-align:top"><p>((&mu;g.h/ml)</p></td><td style="vertical-align:top"><p>(h)</p></td></tr><tr><td colspan="6" style="vertical-align:top"><p>Amoxicillin</p></td></tr><tr><td style="vertical-align:top"><p>AMX/CA</p><p>500/125 mg</p></td><td style="vertical-align:top"><p>500</p></td><td style="vertical-align:top"><p>7.19</p><p>&plusmn; 2.26</p></td><td style="vertical-align:top"><p>1.5</p><p>(1.0-2.5)</p></td><td style="vertical-align:top"><p>53.5</p><p>&plusmn; 8.87</p></td><td style="vertical-align:top"><p>1.15</p><p>&plusmn; 0.20</p></td></tr><tr><td colspan="6" style="vertical-align:top"><p>Clavulanic acid</p></td></tr><tr><td style="vertical-align:top"><p>AMX/CA</p><p>500 mg/125 mg</p></td><td style="vertical-align:top"><p>125</p></td><td style="vertical-align:top"><p>2.40</p><p>&plusmn; 0.83</p></td><td style="vertical-align:top"><p>1.5</p><p>(1.0-2.0)</p></td><td style="vertical-align:top"><p>15.72</p><p>&plusmn; 3.86</p></td><td style="vertical-align:top"><p>0.98</p><p>&plusmn; 0.12</p></td></tr><tr><td colspan="6" style="vertical-align:top"><p>AMX &ndash; amoxicillin, CA &ndash; clavulanic acid</p><p>* Median (range)</p></td></tr></tbody></table><p>Amoxicillin and clavulanic acid serum concentrations achieved with amoxicillin/clavulanic acid are similar to those produced by the oral administration of equivalent doses of amoxicillin or clavulanic acid alone.</p><p><strong><u>Distribution</u></strong></p><p>About 25% of total plasma clavulanic acid and 18% of total plasma amoxicillin is bound to protein. The apparent volume of distribution is around 0.3-0.4 l/kg for amoxicillin and around 0.2 l/kg for clavulanic acid.</p><p>Following intravenous administration, both amoxicillin and clavulanic acid have been found in gall bladder, abdominal tissue, skin, fat, muscle tissues, synovial and peritoneal fluids, bile and pus. Amoxicillin does not adequately distribute into the cerebrospinal fluid.</p><p>From animal studies there is no evidence for significant tissue retention of drug-derived material for either component. Amoxicillin, like most penicillins, can be detected in breast milk. Trace quantities of clavulanic acid can also be detected in breast milk (see section 4.6).</p><p>Both amoxicillin and clavulanic acid have been shown to cross the placental barrier (see section 4.6).</p><p><strong><u>Biotransformation</u></strong></p><p>Amoxicillin is partly excreted in the urine as the inactive penicilloic acid in quantities equivalent to up to 10 to 25% of the initial dose. Clavulanic acid is extensively metabolized in man and eliminated in urine and faeces and as carbon dioxide in expired air.</p><p><strong><u>Elimination</u></strong></p><p>The major route of elimination for amoxicillin is via the kidney, whereas for clavulanic acid it is by both renal and non-renal mechanisms.</p><p>Amoxicillin/clavulanic acid has a mean elimination half-life of approximately one hour and a mean total clearance of approximately 25 l/h in healthy subjects.&nbsp; Approximately 60 to 70% of the amoxicillin and approximately 40 to 65% of the clavulanic acid are excreted unchanged in urine during the first 6 h after administration of single (amoxicillin and clavulanic acid) 250 mg/125 mg or 500 mg/125 mg tablets. Various studies have found the urinary excretion to be 50-85% for amoxicillin and between 27-60% for clavulanic acid over a 24 hour period. In the case of clavulanic acid, the largest amount of drug is excreted during the first 2 hours after administration.</p><p>Concomitant use of probenecid delays amoxicillin excretion but does not delay renal excretion of clavulanic acid (see section 4.5).</p><p><strong><u>Age</u></strong></p><p>The elimination half-life of amoxicillin is similar for children aged around 3 months to<br />2 years and older children and adults. For very young children (including preterm newborns) in the first week of life the interval of administration should not exceed twice daily administration due to immaturity of the renal pathway of elimination. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function.</p><p><strong><u>Gender</u></strong></p><p>Following oral administration of amoxicillin/clavulanic acid to healthy males and female subjects, gender has no significant impact on the pharmacokinetics of either amoxicillin or clavulanic acid.</p><p><strong><u>Renal impairment</u></strong></p><p>The total serum clearance of amoxicillin/clavulanic acid decreases proportionately with decreasing renal function. The reduction in drug clearance is more pronounced for amoxicillin than for clavulanic acid, as a higher proportion of amoxicillin is excreted <em>via </em>the renal route. Doses in renal impairment must therefore prevent undue accumulation of amoxicillin while maintaining adequate levels of clavulanic acid (see section 4.2).</p><p><strong><u>Hepatic impairment</u></strong></p><p>Hepatically impaired patients should be dosed with caution and hepatic function monitored at regular intervals</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Nonclinical data reveal no special hazard for humans based on studies of safety pharmacology, genotoxicity and toxicity to reproduction.</p><p>Repeat dose toxicity studies performed in dogs with amoxicillin/clavulanic acid demonstrate gastric irritancy and vomiting, and discoloured tongue.</p><p>Carcinogenicity studies have not been conducted with amoxicillin/clavulanic acid or its components</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <table border="0" cellspacing="0" cellpadding="0" style="width:522px"><tbody><tr><td style="vertical-align:top"><p><strong><u>Inactive Ingredients</u></strong></p></td></tr><tr><td style="vertical-align:top"><ol><li>Citric acid, anhydrous</li></ol></td></tr><tr><td style="vertical-align:top"><ol><li>Sodium citrate</li></ol></td></tr><tr><td style="vertical-align:top"><ol><li>Sodium benzoate</li></ol></td></tr><tr><td style="vertical-align:top"><ol><li>Microcrystalline cellulose</li></ol></td></tr><tr><td style="vertical-align:top"><ol><li>Xanthan gum</li></ol></td></tr><tr><td style="vertical-align:top"><ol><li>Colloidal silicon dioxide</li></ol></td></tr><tr><td style="vertical-align:top"><ol><li>Strawberry dry flavour</li></ol></td></tr><tr><td style="vertical-align:top"><ol><li>Saccharin sodium</li></ol></td></tr><tr><td style="vertical-align:top"><ol><li>Mannitol</li></ol></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>None</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                24 months
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Before reconstitution, store below 30<sup>o</sup>C, in a dry place, protected from light.</p><p>After reconstitution, store in a refrigerator (2-8<sup>o</sup>C) and use within 7 days. Shake well before use.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pack of 100 mL (when reconstituted) filled in an amber color glass bottle (type III, USP) sealed with induction sealing &amp; white PP CRC cap, packed in a printed carton along with a leaflet and measuring spoon.</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><u>Directions for reconstitution:</u></strong></p><p>Loosen powder, add approximately 60mL of water or add water to <sup>2</sup>&frasl;<sub>3</sub> of the mark on the bottle and shake vigorously in an inverted position, allow it to stand for 5 minutes and then add water up to the mark and shake vigorously until a homogeneous suspension is achieved. Shake well before taking each dose.</p><p>&nbsp;&nbsp;&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Gulf Pharmaceutical Industries - Julphar
Digdaga, Airport Street
Ras Al Khaimah - United Arab Emirates
P.O. Box 997
Tel. No.: (9717) 2 461 461
Fax No.: (9717) 2 462 462


            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                28. March. 2022
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>